NCT01619345View on ClinicalTrials.gov

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

DiabetesHealthy

Interventions

DRUG

semaglutide

Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.

Trial Locations (1)

NG11 6JS

Nottingham

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT01619345 - Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter